Skip to content
ATLAS PREP HQ
Healing

TB-500

Synthetic thymosin-beta-4-derived research peptide, commonly associated with the Ac-LKKTETQ active region

Thymosin beta-4 fragment research focused on tissue repair, wound healing, cell migration, and angiogenesis.

Preclinical Evidence

Route

Subcutaneous research use.

Common format

10 mg vial

Research focus

wound healing

Evidence level

Preclinical Evidence

Typical cycle

8–12 weeks

Healing research motifHealing

TB-500 in 30 seconds

Atlas Fast Read

What it is

Synthetic thymosin-beta-4-derived research peptide, commonly associated with the Ac-LKKTETQ active region

Why people care

Thymosin beta-4 fragment research focused on tissue repair, wound healing, cell migration, and angiogenesis.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

TB-500 is scientifically interesting for wound healing, angiogenesis, but the current case is driven mainly by cell and animal data.

Overview

What is TB-500?

TB-500 is synthetic thymosin-beta-4-derived research peptide, commonly associated with the Ac-LKKTETQ active region. Thymosin beta-4 fragment research focused on tissue repair, wound healing, cell migration, and angiogenesis.

TB-500 is a research/commercial name tied to thymosin beta-4 biology and its active regions. Thymosin beta-4 has decades of wound-healing research, but 'TB-500' products are not an approved standardized medicine.

Mechanism

How it works

Thymosin-beta-4-related sequences bind actin and influence cytoskeletal dynamics, cell migration, angiogenesis, and wound repair. Specific 'TB-500' pharmacology is less standardized than the broader thymosin-beta-4 literature.

Research areas

wound healingangiogenesistendon/muscle repaircardiac repair models

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

There is no established controlled human evidence for 'TB-500' as a standardized injury-recovery drug. Human studies of full thymosin beta-4 or related products should not be treated as direct proof for underground TB-500 formulations.

Preclinical evidence

Thymosin-beta-4 and related sequence research shows actin binding, cell migration, angiogenesis, and wound-repair effects in animals. Specific underground TB-500 products are not necessarily equivalent to the studied molecules.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources experimental reference: 500–1,000 mcg/day. There is no validated human dose for 'TB-500' as a standardized drug.

Frequency

Once daily in the community current page.

Timing

No established timing requirement.

Route

Subcutaneous research use.

Cycle length

8–12 weeks

Reconstitution

Community reference: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C, protected from light, and do not refreeze.

Monitoring

No validated monitoring. Track objective tissue/injury function and adverse effects; CBC/CMP are general safety context. Athletes should note anti-doping restrictions around thymosin-beta-4-related substances.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Controlled human safety data are limited. Possible issues include injection-site reactions, headache, nausea, dizziness, fatigue and hypersensitivity. Because several proposed mechanisms involve angiogenesis or tissue-growth signaling, long-term systemic effects are uncertain.

Contraindications

No validated human contraindication profile exists. Pregnancy/breastfeeding, active malignancy, unexplained masses, major bleeding disorders or serious systemic illness warrant avoidance outside formal research/medical oversight.

Interactions

Formal interaction studies are lacking. Use with anticoagulants/antiplatelet drugs, growth-factor therapies, immunomodulators or other experimental repair peptides creates unknown additive risks.

Stacks

Common stacks

BPC-157 + TB-500

Common recovery pairing intended to combine complementary repair pathways.

Preclinical/community use; combination not clinically validated.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

TB-500 is scientifically interesting for wound healing, angiogenesis, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Healing

Healing

Ara-290

Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Read guide

Healing

BPC-157

Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Read guide

Healing

BPC-157 + TB-500

Combination research pairing BPC-157 and TB-500 for tissue repair, wound healing, and musculoskeletal recovery.

Read guide